Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Obsessive-Compulsive Disorder (OCD)

DMT for Obsessive-Compulsive Disorder (OCD)

1 paper and 0 clinical trials exploring dmt as a treatment for obsessive-compulsive disorder (ocd).

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationAbout 1-2% of the population worldwide.

Obsessive-Compulsive Disorder (OCD)

Recent research indicates that psychedelics, particularly psilocybin, are emerging as potential therapeutic agents in the treatment of Obsessive-Compulsive Disorder (OCD). Early clinical trials demonstrate promising results regarding their efficacy and safety, paving the way for future studies in this field.

Full Obsessive-Compulsive Disorder (OCD) profile

Academic Research

1 paper
Open Accessindividual

Inhaled N, N-dimethyltryptamine diminishes connectivity between the ventral tegmental area and the nucleus accumbens: relevance to pathologies of mesolimbic and mesocortical pathways

In a within-subject pharmacoimaging study of 11 healthy psychedelic-experienced volunteers, inhaled DMT acutely reduced connectivity between the left ventral tegmental area and the right nucleus accumbens while increasing connectivity between the nucleus accumbens and anterior cingulate cortex and between the medial prefrontal cortex and anterior cingulate. These connectivity shifts correlated with changes in volition and perception and suggest a potential therapeutic mechanism for disorders of reward processing.

Published
December 12, 2025
Journal
Scientific Reports
Authors
Lima, G., Soares, C., Teixeira, M., Pais, M., Cabral, C., Rijo, P., Castelo-Branco, M.

Clinical Trials

0 trials

No clinical trials have been tagged with both DMT and Obsessive-Compulsive Disorder (OCD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all DMT papers Search all Obsessive-Compulsive Disorder (OCD) trials Full DMT profile Full Obsessive-Compulsive Disorder (OCD) profile